Data on 216 diabetes patients showed 44.1% of those who took exenatide once a week attained an A1C of 7% or less, compared with only 11.4% in those who had insulin detemir treatment. Researchers also found patients in the exenatide group lost about 6 pounds, compared with a gain of about 1.8 pounds in the detemir group. The results appear in Diabetes Care.
Exenatide outperforms detemir in A1C reduction
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|